Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, …
Macro
US · Macroeconomic Factors/Risks · ForecastsRain Therapeutics Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)
Likelihood Legend A++ is best, F- worst
- A++
- A+
- A
-
Very Unlikely - B+
- B
-
Unlikely
- C+
- C
- D+
- D
- D-
-
Avg.
- E+
- E-
-
Unlikely - F+
- F
- F-
-
Very Unlikely
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.